Burning Rock

Burning Rock Dx is a global diagnostics company focused on applying next-generation sequencing (NGS) to precision oncology. Guided by its mission, “Guard Life via Science,” the company develops diagnostic solutions for tissue and blood samples and supports work across the precision oncology development cycle. Its portfolio includes testing for solid tumors, minimal residual disease, and hematologic malignancies, as well as multi-omics detection for research use. Burning Rock also provides early cancer detection, pharma biomarker and companion diagnostic services, international diagnostics, and sequencing services.

The company’s NGS-based assays include targeted panels designed to identify cancer biomarkers, while its in-house database supports clinical trial studies and research. Burning Rock highlights quality systems supporting clinical laboratory testing, clinical trials, and product development, alongside global regulatory expertise and customer services such as kit shipment, sample collection, billing, and reporting. Its offerings serve biopharmaceutical partners, laboratories, clinicians, and researchers working to advance oncology research and precision diagnosis.